Kazia Therapeutics

Kazia Therapeutics is an ASX- and NASDAQ-listed biotechnology company. It is developing the PI3K/mTOR inhibitor GDC-0084 for brain cancer and Cantrixil for ovarian cancer. GDC-0084 was in-licensed from Genentech in 2016.

Equities

Equities by Sector

Sectors

Thematics

Latest

Inside the mind of investors: International Biotechnology Trust

Borussia Dortmund – executive interviews

UK equities: A generational opportunity?

Audiovisual

Latest

Take on Trusts – December 2024

Vantage: Gresham House Energy Storage Fund – Navigating challenges in energy storage

IP Group – executive interview

About Edison

About Edison

Careers

Kazia Therapeutics (NASDAQ: KZIA)

Latest Insights

Kazia Therapeutics — Reinvestment period with increased R&D focus

Kazia Therapeutics — Collaboration may expand utility to combo therapies

Kazia Therapeutics — EVT801 data published in peer-reviewed journal

Kazia Therapeutics — Q123 cash flows in line with our estimates

EVT801, Kazia’s second programme, and capital markets

Paxalisib: Beyond glioblastoma and commercial opportunity

Meet Kazia’s management team and hear about paxalisib, Kazia’s lead programme

Kazia Therapeutics — Several upcoming catalysts

Kazia Therapeutics: Edison Open House Healthcare 2022

Kazia Therapeutics – introducing novel asset EVT-801

Kazia Therapeutics — Multiple paxalisib data points expected in Q4

Kazia Therapeutics — Multiple paxalisib data points expected in Q4

Kazia Therapeutics – overview and update with CEO James Garner

Kazia Therapeutics — New asset to target tumor lymphangiogenesis

Kazia Therapeutics — New asset to target tumor lymphangiogenesis

Kazia Therapeutics — Paxalisib Chinese rights licensed

Kazia Therapeutics — Paxalisib Chinese rights licensed

Kazia Therapeutics — All in on GBM AGILE, but eyes on brain mets

Kazia Therapeutics — All in on GBM AGILE, but eyes on brain mets

Kazia Therapeutics – Edison Open House interview

Kazia Therapeutics — Cantrixil final Phase I data reported

Kazia Therapeutics — Cantrixil final Phase I data reported

Kazia Therapeutics — Phase IIa shows good safety, consistent efficacy

Kazia Therapeutics — Phase IIa shows good safety, consistent efficacy

Kazia Therapeutics — Bringing a vetted drug class to the brain

Kazia Therapeutics — Paxalisib trial still on track for H220 start

Kazia Therapeutics — An agile pivot

Kazia Therapeutics — An agile pivot

Kazia Therapeutics — GDC-0084 – encouraging initial efficacy

Executive interview – Kazia Therapeutics

Kazia Therapeutics — GDC-0084 – encouraging initial efficacy

Kazia Therapeutics — GDC-0084 gets a fifth collaboration

Kazia Therapeutics — Higher MTD, new collaboration for GDC-0084

Kazia Therapeutics — Higher MTD, new collaboration for GDC-0084

Kazia Therapeutics — Cantrixil efficacy data presented at AACR

Kazia Therapeutics — Cantrixil efficacy data presented at AACR

Kazia Therapeutics — New indications for GDC-0084

Kazia Therapeutics — New indications for GDC-0084

Kazia Therapeutics — GDC-0084 and Cantrixil trials progressing

Kazia Therapeutics — GDC-0084 and Cantrixil trials progressing

Kazia Therapeutics — GDC-0084 Phase II underway

Kazia Therapeutics — GDC-0084 Phase II underway

Novogen — GDC-0084 Phase II on track to commence Q417

Novogen — GDC-0084 Phase II on track to commence Q417

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Novogen — Update 31 October 2016

Novogen — Update 11 May 2016

Novogen — Update 9 May 2016